No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs533531305 |
chr9:136620179-136620180 |
ZNF genes & repeats Weak transcription Flanking Bivalent TSS/Enh Bivalent Enhancer Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
2 |
rs574763926 |
chr9:136620198-136620199 |
ZNF genes & repeats Weak transcription Flanking Bivalent TSS/Enh Bivalent Enhancer Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs535686415 |
chr9:136620224-136620225 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs372391490 |
chr9:136620238-136620239 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs572109499 |
chr9:136620255-136620256 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs77635574 |
chr9:136620258-136620259 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs564121973 |
chr9:136620259-136620260 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs575664214 |
chr9:136620297-136620298 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs372921347 |
chr9:136620300-136620301 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs542990987 |
chr9:136620357-136620358 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs562094102 |
chr9:136620362-136620363 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs529536763 |
chr9:136620416-136620417 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs182809673 |
chr9:136620424-136620425 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs559645836 |
chr9:136620465-136620466 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs555034629 |
chr9:136620498-136620499 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs375490003 |
chr9:136620549-136620550 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs667420 |
chr9:136620568-136620569 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
18 |
rs2428106 |
chr9:136620584-136620585 |
Strong transcription Weak transcription Bivalent Enhancer Flanking Active TSS Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
19 |
rs375922027 |
chr9:136620601-136620602 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs187097271 |
chr9:136620614-136620615 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs549387933 |
chr9:136620641-136620642 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs78478497 |
chr9:136620653-136620654 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs2502763 |
chr9:136620747-136620748 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
24 |
rs553954930 |
chr9:136620754-136620755 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs9409857 |
chr9:136620755-136620756 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
26 |
rs533353456 |
chr9:136620767-136620768 |
Strong transcription Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs200997412 |
chr9:136620808-136620809 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs113517537 |
chr9:136620819-136620820 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs372895064 |
chr9:136620833-136620834 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs374809728 |
chr9:136620838-136620839 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs377577373 |
chr9:136620839-136620840 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs111309128 |
chr9:136620840-136620841 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs201120833 |
chr9:136620842-136620843 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs201938693 |
chr9:136620848-136620849 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs192099574 |
chr9:136620850-136620851 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs112168794 |
chr9:136620851-136620852 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs200534612 |
chr9:136620858-136620859 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs112709184 |
chr9:136620873-136620874 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs539602419 |
chr9:136620890-136620891 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs10435927 |
chr9:136620892-136620893 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs142738489 |
chr9:136620915-136620916 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs543056649 |
chr9:136620963-136620964 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs59586707 |
chr9:136620998-136620999 |
Strong transcription Weak transcription Enhancers Flanking Bivalent TSS/Enh
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
44 |
rs192264822 |
chr9:136621039-136621040 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs535807800 |
chr9:136621041-136621042 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs541337889 |
chr9:136621043-136621044 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs549717152 |
chr9:136621108-136621109 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs57327828 |
chr9:136621149-136621150 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
49 |
rs373846342 |
chr9:136621150-136621151 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs115725529 |
chr9:136621176-136621177 |
Strong transcription Enhancers Weak transcription Bivalent Enhancer
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|